Levels of cholesterol in small LDL particles predict atherosclerosis progression and incident CHD in the HDL-Atherosclerosis Treatment Study (HATS).

Test whether angiographically-documented changes in percent stenosis and clinical endpoints (coronary-related deaths, myocardial infarctions, stroke, revascularization for worsening ischemia) in the HDL-Atherosclerosis Treatment Study (HATS) were attributable to specific LDL-subclasses.Gradient gel...

Full description

Bibliographic Details
Main Authors: Paul T Williams, Xue-Qiao Zhao, Santica M Marcovina, B Greg Brown, Ronald M Krauss
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3584097?pdf=render
_version_ 1819067872328024064
author Paul T Williams
Xue-Qiao Zhao
Santica M Marcovina
B Greg Brown
Ronald M Krauss
author_facet Paul T Williams
Xue-Qiao Zhao
Santica M Marcovina
B Greg Brown
Ronald M Krauss
author_sort Paul T Williams
collection DOAJ
description Test whether angiographically-documented changes in percent stenosis and clinical endpoints (coronary-related deaths, myocardial infarctions, stroke, revascularization for worsening ischemia) in the HDL-Atherosclerosis Treatment Study (HATS) were attributable to specific LDL-subclasses.Gradient gel electrophoresis of on-study LDL-subclass cholesterol concentrations were measured in 32 placebo, 33 simvastatin-niacin, 38 antioxidant, and 39 simvastatin-niacin & antioxidant treated participants. The prespecified primary end point was the mean change per patient from the initial arteriogram to the final arteriogram in the percent stenosis caused by the most severe lesion in each of the nine proximal coronary segments.The change in the percent stenosis of the most severe proximal lesions increased in association with higher concentrations of the small LDL subfractions LDL-IIIb (24.2-24.6 nm) and LDL-IVa (23.3-24.1 nm) before (both P = 0.002) and after (P = 0.01 and P = 0.03 respectively) adjustment for treatment group and on-study HDL-cholesterol, LDL-cholesterol, and triglyceride concentrations. The associations appeared specific to lesions with <30% baseline stenosis. When adjusted for age, sex, baseline BMI and cigarette use, the odds for primary clinical endpoints (death from coronary causes, nonfatal myocardial infarction, stroke, or revascularization for worsening ischemia) were significantly greater in subjects with higher on-study LDL-IIIb levels both before (P = 0.01) and after (P = 0.03) adjustment for treatment group and the standard lipid values.Plasma LDL-IIIb cholesterol concentrations were related to changes in coronary artery stenosis and cardiovascular events in patients with coronary artery disease and low HDL-cholesterol.ClinicalTrials.gov NCT00000553.
first_indexed 2024-12-21T16:25:09Z
format Article
id doaj.art-caeb8761d5db49ca98118cdcef9d575a
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-12-21T16:25:09Z
publishDate 2013-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-caeb8761d5db49ca98118cdcef9d575a2022-12-21T18:57:29ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-0182e5678210.1371/journal.pone.0056782Levels of cholesterol in small LDL particles predict atherosclerosis progression and incident CHD in the HDL-Atherosclerosis Treatment Study (HATS).Paul T WilliamsXue-Qiao ZhaoSantica M MarcovinaB Greg BrownRonald M KraussTest whether angiographically-documented changes in percent stenosis and clinical endpoints (coronary-related deaths, myocardial infarctions, stroke, revascularization for worsening ischemia) in the HDL-Atherosclerosis Treatment Study (HATS) were attributable to specific LDL-subclasses.Gradient gel electrophoresis of on-study LDL-subclass cholesterol concentrations were measured in 32 placebo, 33 simvastatin-niacin, 38 antioxidant, and 39 simvastatin-niacin & antioxidant treated participants. The prespecified primary end point was the mean change per patient from the initial arteriogram to the final arteriogram in the percent stenosis caused by the most severe lesion in each of the nine proximal coronary segments.The change in the percent stenosis of the most severe proximal lesions increased in association with higher concentrations of the small LDL subfractions LDL-IIIb (24.2-24.6 nm) and LDL-IVa (23.3-24.1 nm) before (both P = 0.002) and after (P = 0.01 and P = 0.03 respectively) adjustment for treatment group and on-study HDL-cholesterol, LDL-cholesterol, and triglyceride concentrations. The associations appeared specific to lesions with <30% baseline stenosis. When adjusted for age, sex, baseline BMI and cigarette use, the odds for primary clinical endpoints (death from coronary causes, nonfatal myocardial infarction, stroke, or revascularization for worsening ischemia) were significantly greater in subjects with higher on-study LDL-IIIb levels both before (P = 0.01) and after (P = 0.03) adjustment for treatment group and the standard lipid values.Plasma LDL-IIIb cholesterol concentrations were related to changes in coronary artery stenosis and cardiovascular events in patients with coronary artery disease and low HDL-cholesterol.ClinicalTrials.gov NCT00000553.http://europepmc.org/articles/PMC3584097?pdf=render
spellingShingle Paul T Williams
Xue-Qiao Zhao
Santica M Marcovina
B Greg Brown
Ronald M Krauss
Levels of cholesterol in small LDL particles predict atherosclerosis progression and incident CHD in the HDL-Atherosclerosis Treatment Study (HATS).
PLoS ONE
title Levels of cholesterol in small LDL particles predict atherosclerosis progression and incident CHD in the HDL-Atherosclerosis Treatment Study (HATS).
title_full Levels of cholesterol in small LDL particles predict atherosclerosis progression and incident CHD in the HDL-Atherosclerosis Treatment Study (HATS).
title_fullStr Levels of cholesterol in small LDL particles predict atherosclerosis progression and incident CHD in the HDL-Atherosclerosis Treatment Study (HATS).
title_full_unstemmed Levels of cholesterol in small LDL particles predict atherosclerosis progression and incident CHD in the HDL-Atherosclerosis Treatment Study (HATS).
title_short Levels of cholesterol in small LDL particles predict atherosclerosis progression and incident CHD in the HDL-Atherosclerosis Treatment Study (HATS).
title_sort levels of cholesterol in small ldl particles predict atherosclerosis progression and incident chd in the hdl atherosclerosis treatment study hats
url http://europepmc.org/articles/PMC3584097?pdf=render
work_keys_str_mv AT paultwilliams levelsofcholesterolinsmallldlparticlespredictatherosclerosisprogressionandincidentchdinthehdlatherosclerosistreatmentstudyhats
AT xueqiaozhao levelsofcholesterolinsmallldlparticlespredictatherosclerosisprogressionandincidentchdinthehdlatherosclerosistreatmentstudyhats
AT santicammarcovina levelsofcholesterolinsmallldlparticlespredictatherosclerosisprogressionandincidentchdinthehdlatherosclerosistreatmentstudyhats
AT bgregbrown levelsofcholesterolinsmallldlparticlespredictatherosclerosisprogressionandincidentchdinthehdlatherosclerosistreatmentstudyhats
AT ronaldmkrauss levelsofcholesterolinsmallldlparticlespredictatherosclerosisprogressionandincidentchdinthehdlatherosclerosistreatmentstudyhats